Overexpression of miR-184 disrupts the blood-brain barrier and larval locomotion. by Sravya Paluri (5475260)

HFD changes lysosomal activity. by Tong Yue (6033305)

miR-184 does not downregulate target pSJ and TCJ mRNA levels but changes Nrv2 expression. by Sravya Paluri (5475260)

Mediation effect of muscle strength on the associations of obesity with incidence of knee OA. by Laijun Yan (19797455)

Recognition of <i>F. novicida</i> strains by lysophagosomes and lysosomes in THP-1 cells. by Dhandy Koesoemo Wardhana (21956781)

Recognition of <i>F. novicida</i> strains by lysophagosomes and lysosomes in HeLa–FcγRII cells. by Dhandy Koesoemo Wardhana (21956781)

Overexpression of miR-184 disrupts pleated septate junctions in peripheral nerves. by Sravya Paluri (5475260)

Expression levels of lysosome-related genes in HFD-fed flies and control group. by Tong Yue (6033305)

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Normal odor or shock acuity in Rubicon RNAi or Atg1 overexpression flies. by Tong Yue (6033305)

Knockdown efficiency of lysosome-related genes in RNAi lines. by Tong Yue (6033305)

Transient suppression of <i>atg5</i> in neurons does not impair ITM. by Tong Yue (6033305)

Elevated autophagic levels in neurons restore HFD-induced memory impairment. by Tong Yue (6033305)

Recognition of <i>F. novicida</i> strains by the mitochondria and Golgi complex in THP-1 cells. by Dhandy Koesoemo Wardhana (21956781)

Intracellular growth of the wild-type strain and <i>FTN_0096</i> mutant in THP-1 cells. by Dhandy Koesoemo Wardhana (21956781)

Recognition of <i>F. novicida</i> strains by the mitochondria and Golgi complex in HeLa–FcγRII cells. by Dhandy Koesoemo Wardhana (21956781)